Effects of Combined Interventions to Optimize Recovery During High-intensity Exercises in Healthy Adults

June 30, 2021 updated by: Swiss Federal Institute of Technology
The objective of the study is to evaluate the effects a complex recovery intervention during the breaks of a repeated sprint test on exercise performance compared to placebo and control conditions. The enhanced recovery package (ERP) includes neck cooling with an iced gel pad, drinking a 6% CHO solution, mouth-rinsing with a 10% CHO, 6 mg・kg -1 caffeine solution, performing submaximal squats and hyperventilating a hyperoxic mixture; all applied in each 3-min break in-between the six 30-s sprints. This intervention will be compared to a placebo and a control condition.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

16

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • ZH
      • Zürich, ZH, Switzerland, 8057
        • ETH Zürich, Exercise Physiology Lab

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Informed Consent as documented by signature (Appendix Informed Consent Form)
  • Healthy
  • Male
  • Age: 18-40 years
  • Body-Mass-Index (BMI): 18.5-24.9 kg・m-2
  • Trained individuals: max. Power output ≥ 4.0 Watts・kg-1
  • Non-smoking
  • Willingness to adhere to the study rules

Exclusion Criteria:

  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participants
  • Previous enrolment into the current study
  • Intake of medications affecting performance or the respiratory, cardiovascular or neuromuscular system
  • Acute or chronic illness affecting performance or the respiratory, cardiovascular or neuromuscular system

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ERP Intervention
Combination of different methods to improve recovery.

The ERP intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.

ERP: 1) neck cooling with an iced gel pad, 2) drinking a ∼ 6% CHO solution, 3) mouth-rinsing with a ∼10% CHO, ∼6 mg ・ kg -1 caffeine solution, 4) performing submaximal squats and 5) hyperventilating a hyperoxic mixture

No Intervention: Control
Passive recovery by sitting on a chair
Placebo Comparator: Placebo
A combination of methods similar to the ERP intervention but at an intensity / mixture supposed to be ineffective at improving recovery.

The control intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.

1) neck "cooling" with room temperature gel pack, 2) drinking an artificially sweetened solution, 3) mouth-rinsing with artificially sweetened solution (containing no caffeine), 4) performing unloaded squat manoeuvres, 5) deep breaths with room air

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in mean power output
Time Frame: through study completion, an expected average of 3 weeks per participant
Measured over the six 30s high-intensity cycling sprints in each of the three conditions. Mean power mirrors the body's ability to generate muscle power and physical energy. Any meaningful effects of the recovery interventions will eventually translate into a higher power output.
through study completion, an expected average of 3 weeks per participant
Change in fatigue index
Time Frame: through study completion, an expected average of 3 weeks per participant
Fatigue index = drop in power output from the beginning to the end a 30s sprint test. The change in this index will be calculated from the 1st to the 6th sprint test in each condition.
through study completion, an expected average of 3 weeks per participant

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Christina M. Spengler, Prof., Christina M. Spengler, Prof. Study Principal Investigator Exercise Physiology Lab, Institute of Human Movement Sciences and Sport, ETH Zurich

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 10, 2020

Primary Completion (Actual)

June 30, 2021

Study Completion (Actual)

June 30, 2021

Study Registration Dates

First Submitted

August 4, 2020

First Submitted That Met QC Criteria

August 7, 2020

First Posted (Actual)

August 11, 2020

Study Record Updates

Last Update Posted (Actual)

July 2, 2021

Last Update Submitted That Met QC Criteria

June 30, 2021

Last Verified

October 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • ERP_2020

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on ERP

3
Subscribe